This trial will evaluate the effectiveness of mirikizumab in treating Crohn's disease.
- Crohn's Disease
2 Primary · 5 Secondary · Reporting Duration: Week 52
2 Treatment Groups
Mirikizumab IV and SC
1 of 2
1 of 2
778 Total Participants · 2 Treatment Groups
Primary Treatment: Mirikizumab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is there a risk of serious side effects from taking Mirikizumab?
"Mirikizumab has received a score of 3 for safety. This is because it is in Phase 3 clinical trials, so there is data supporting both its efficacy and safety from multiple rounds of testing." - Anonymous Online Contributor
Does this study represent a new approach to research?
"Since 2018, the pharmaceutical company Eli Lilly and Company has been researching mirikizumab. The first study involving 1281 people occurred in 2018. After this initial trial, mirikizumab received Phase 3 drug approval and there are now 7 active studies being conducted across 656 cities and 40 countries." - Anonymous Online Contributor
What is the precedent for Mirikizumab's efficacy?
"Right now, there are 7 distinct research programs underway for Mirikizumab. Of those, 6 are in the critical third stage of testing. Most of the clinical trials related to Mirikizumab are taking place in Warszawa and New South Wales; however, 2942 different locations around the world are running studies concerning this treatment." - Anonymous Online Contributor
What are the researchers investigating with this clinical trial?
"The primary outcome being measured by Eli Lilly and Company, the study's sponsor, over the course of 52 weeks is Percentage of Participants Achieving Clinical Remission. Additionally, this trial will evaluate Change from Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ), Percentage of Participants Achieving Endoscopic Remission, and Percentage of Participants Achieving Clinical Response as secondary outcomes." - Anonymous Online Contributor
To date, how many people have agreed to take part in this research?
"In order to successfully run this trial, 778 patients who meet the pre-specified inclusion criteria are needed. These potential participants can be based out of locations such as Private Practice - Dr. Bruce Musgrave in Kentville, Nova Scotia and Washington University Medical School in Saint Louis, Missouri." - Anonymous Online Contributor
In how many different medical practices is this medical study being overseen today?
"This study is being conducted out of numerous locations, some of which are Private Practice - Dr. Bruce Musgrave in Kentville, Nova Scotia, Washington University Medical School in Saint Louis, Missouri, and Capital Digestive Care in Rockville, Maryland." - Anonymous Online Contributor
Are there any opportunities for patients to participate in this research?
"That is correct, the online information from clinicaltrials.gov corroborates that this study is actively looking for subjects to participate. The listing was first posted on 6/22/2020 and updated as recently as 11/10/2022. So far, they have 85 locations signed up but need 778 people total to fill the trial." - Anonymous Online Contributor